Invex Therapeutics Ltd. (AU:IXC) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Invex Therapeutics Ltd. has announced promising results from their collaboration with Tessara Therapeutics, showing that Exenatide significantly improves neuronal cell survival in a 3D human brain model of Alzheimer’s Disease. The study highlights Exenatide’s potential in increasing cell viability and its role as a GLP-1 receptor agonist in protecting against Alzheimer’s, a market valued at $17 billion in 2023. These findings could pave the way for further exploration of Exenatide in treating other neurodegenerative diseases.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.